跳至主要内容
临床试验/EUCTR2015-002602-36-DE
EUCTR2015-002602-36-DE进行中(未招募)1 期

Efficacy and safety of high dose glucocorticosteroid treatment for idiopathic sudden sensorineural hearing loss (HODOKORT) - HODOKORT

Martin-Luther-Universität Halle-Wittenberg0 个研究点目标入组 312 人开始时间: 2016年3月8日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
312

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -female and male adults (18-80 years)
  • -unilateral sensorineural hearing loss
  • -sudden onset of hearing loss (occurring within 24 hours)
  • -unknown etiology (no other ear or CNS disease)
  • -change in hearing threshold due to ISSHL of 30 dB or higher (as compared to a pre-event audiogram, the audiogram of the unaffected ear, or the ISO) for the 3 most affected contiguous frequencies in the affected ear but not less then 50 dB absolute threshold as average of the 3 most affected contiguous frequencies between 0,25 und 8 kHz < 50 dB HL
  • -enrolment and treatment within 7 days from onset
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 156
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 156

排除标准

  • -recurrent ISSHL at the affected side (< 12 months)
  • -known other otologic cause of ISSHL (e.g.: middle ear disease; vestibular schwannoma; known fluctuating hearing loss; Meniere’s disease)
  • -absolute hearing threshold as average of the 3 most affected contiguous frequencies between 0,25 und 8 kHz < 50 dB HL
  • -certain systemic diseases (treatment for or chronically active infection such as HIV, hepatitis C or B, tuberculosis, hard to balance diabetes mellitus, ongoing immunosuppressive treatment for rheumatic or chronic inflammatory disease, unstable atherosclerotic disease, heart failure >NYHA II, suicidality, severe osteoporosis, active peptic ulcer, uncontrolled (syst. >180 mmHg or diast. >100 mmHg) arterial hypertension)
  • -treated mental disorders or after surgical interventions in the last 6 weeks: inclusion only after critical evaluation by the investigator
  • -pre-treatment of ISSHL with glucocorticosteroids or hyperbaric oxygen
  • -conductive deafness (air-bone gap 4PTA0,5-4kHz >10 dB)
  • -pregnancy or lactation

研究者

相似试验